{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma&page=34", "query": { "condition": "Glioma", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 2106, "total_pages": 211, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:04:05.627Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT01156584", "title": "A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Oligoastrocytoma" ], "interventions": [ { "name": "Toca 511 vector", "type": "BIOLOGICAL" }, { "name": "Toca FC", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tocagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2010-07", "completion_date": "2016-08-18", "has_results": false, "last_update_posted_date": "2018-05-21", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01156584" }, { "nct_id": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Esophageal Cancer", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Ovarian Epithelial Cancer", "Carcinoma Breast Stage IV", "Hormone-refractory Prostate Cancer", "Head and Neck Cancers- Squamous Cell", "Renal Cell Cancer", "Urinary Bladder Neoplasms", "Cervical Cancer", "Endometrial Cancer", "Glioblastoma Multiforme", "Triple Negative Breast Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy (SG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2012-12-17", "completion_date": "2020-08-13", "has_results": true, "last_update_posted_date": "2021-08-12", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 12, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01631552" }, { "nct_id": "NCT00532948", "title": "A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "capecitabine [Xeloda]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 24, "start_date": "2007-05", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 9, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00532948" }, { "nct_id": "NCT06743100", "title": "18F-Floretyrosine Expanded Access Program", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Glioma (Any Grade) in the Brain" ], "interventions": [ { "name": "18F-Floretyrosine", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 10, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06743100" }, { "nct_id": "NCT01402063", "title": "PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "PPX (CT2103)", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2011-09", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 9, "location_summary": "La Jolla, California • Scarborough, Maine • Worcester, Massachusetts + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Syracuse", "state": "New York" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01402063" }, { "nct_id": "NCT00883298", "title": "Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma Multiforme", "Recurrent Gliosarcoma" ], "interventions": [ { "name": "temozolomide and bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Center for Neurosciences, Tucson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "83 Years", "sex": "ALL", "summary": "18 Years to 83 Years" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2014-12-01", "has_results": false, "last_update_posted_date": "2017-03-30", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00883298" }, { "nct_id": "NCT05432804", "title": "Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Glioblastoma, IDH-Wildtype", "Recurrent MGMT-Methylated Glioblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2023-03-20", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432804" }, { "nct_id": "NCT00003458", "title": "Antineoplaston Therapy in Treating Children With Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Brain Tumors" ], "interventions": [ { "name": "Antineoplaston therapy (Atengenal + Astugenal)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Months to 18 Years" }, "enrollment_count": 34, "start_date": "1996-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003458" }, { "nct_id": "NCT03587038", "title": "OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "OKN 007", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Photon/Proton IMRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 27, "start_date": "2018-09-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-24T00:04:05.627Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587038" } ] }